MedTrace Logo

Oral Propanolol for Surgically Inaccessible Cavernous Malformations

NCT03523650 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 346

Last updated 2018-05-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the role of propranolol as an alternative treatment for cavernous malformation in patients that may not be ideal candidates for surgery.

Conditions

  • Cavernous Malformations,Cerebral and/or Spinal

Interventions

DRUG

Propranolol Oral Tablet

A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Propranolol Oral tablets, tid, for 36 months.

DRUG

Placebo Oral Tablet

A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Yashar Kalani, MD, PHD · University of Virginia Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-07
Primary Completion
2019-01-31
Completion
2019-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03523650 on ClinicalTrials.gov